Skip to content

革命医药

US · RVMD #499 按市值排名 上市于 2020
177.96 -11.30 -5.97%
实时 - 追踪5344个代码 - 心跳于258秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量增加了4家。
  • 机构持股总比例下降了1.3个百分点。

机构持股

机构持股比例
100.68% -1.31pp
机构数量
819 +4
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund53.03%
Hedge Fund32.38%
VC/PE Fund8.50%
Public Company2.41%
Individual/Insider2.17%
Private Company2.00%
Sovereign Wealth Fund1.11%
Government Pension Fund0.83%
Family Office/Trust0.23%

主要股东 截至 2026-06-30

BlackRock 6.39% · 13.70M 股
Farallon Capital Management, L.L.C. 6.32% · 13.55M 股
FMR 5.60% · 12.00M 股
Baker Bros. Advisors LP 5.34% · 11.44M 股
Janus Henderson Group plc 5.01% · 10.74M 股
Darwin Global Management Limited 4.96% · 10.63M 股
Vanguard Capital Management, LLC 4.84% · 10.38M 股
Vanguard Portfolio Management, LLC 3.87% · 8.29M 股
Nextech Invest Ltd. 3.55% · 7.60M 股
Paradigm Biocapital Advisors LP 2.97% · 6.36M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 15次买入 · 35次卖出

姓名职务持股比例
Alexis Borisy Lead Independent Director 1.09%
Mark Goldsmith Chief Executive Officer 0.37%
Thilo Schroeder Independent Director 0.35%
Stephen Kelsey President of Research & Development 0.10%
Margaret Horn Chief Operating Officer 0.04%
Sandra Horning Independent Director 0.04%
Jack Anders Chief Financial Officer 0.04%
Xiaolin Wang Executive Vice President of Clinical Development 0.03%
Alan Bart Sandler Chief Development Officer 0.02%
Elizabeth Anderson Independent Director 0.02%
Wei Lin Chief Medical Officer 0.02%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-28 Alan Bart Sandler Chief Development Officer Automatic Disposition -309 $203.91–204.72
2026-09-28 Alan Bart Sandler Chief Development Officer Derivative Exercise and Sale -6,000 $58.84–203.91
2026-09-24 Anthony Mancini Chief Global Commercialization Officer Derivative Exercise and Sale -3,121 $33.62–200.54
2026-09-24 Jeffrey Cislini Senior Vice President Automatic Disposition -765 $207.32
2026-09-23 Anthony Mancini Chief Global Commercialization Officer Automatic Disposition -587 $200.00
2026-09-21 Elizabeth Anderson Independent Director Automatic Disposition -5,073 $192.54–195.15
2026-09-21 Elizabeth Anderson Independent Director Derivative Exercise and Sale -5,070 $1.12–192.54
2026-09-17 Anthony Mancini Chief Global Commercialization Officer Automatic Disposition -1,764 $196.94
2026-09-15 Mark Goldsmith Chief Executive Officer Open Market Disposition -13,988 $195.01–199.30
2026-09-15 Margaret Horn Chief Operating Officer Automatic Disposition -4,967 $195.01–199.30
2026-09-15 Stephen Kelsey President of Research & Development Open Market Disposition -5,569 $195.01–199.30
2026-09-15 Alan Bart Sandler Chief Development Officer Automatic Disposition -341 $194.96–199.30
2026-09-15 Anthony Mancini Chief Global Commercialization Officer Open Market Disposition -1,774 $195.05–199.30
2026-09-15 Jack Anders Chief Financial Officer Open Market Disposition -4,053 $195.00–199.30
2026-09-15 Jeffrey Cislini Senior Vice President Open Market Disposition -3,366 $195.01–199.30
2026-09-14 Mark Goldsmith Chief Executive Officer Intent to Sell (Form 144) -13,603 $203.77
2026-09-14 Margaret Horn Chief Operating Officer Intent to Sell (Form 144) -4,830 $203.77
2026-09-14 Stephen Kelsey President of Research & Development Intent to Sell (Form 144) -5,415 $203.77
2026-09-14 Alan Bart Sandler Chief Development Officer Intent to Sell (Form 144) -331 $203.77
2026-09-14 Anthony Mancini Chief Global Commercialization Officer Intent to Sell (Form 144) -2,377 $203.77

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:13 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

革命医药 讨论区 0 条评论

发表评论